Institutional Rotation & Setup for Potential Re-Rating in 2025

4月10日

I have outlined some areas of interest in the chart and some possible ways to reach 2.50 area. Below my personal thoughts behind this.

Institutional Activity & Accumulation
• Mirabella Financial Services LLP holds 10.48% (77.6M shares); estimated VWAP entry: ~1.4217 NOK.
• Alden AS holds 32M shares (4.3%) and remains a large holder after trimming slightly.
• Previous active players in 2024 (Skøien AS, Tigerstaden AS, Dukat AS) have exited, marking a rotation.
• Institutional base is solidifying — setting the stage for potential re-rating in 2025.

Technical Structure
• Institutional accumulation range: 1.10 – 1.30 NOK.
• Strong historical bid defense around 1.150 – 1.160 NOK.
• Previous resistance: 1.40 – 1.45 NOK. Break above this level could trigger expansion leg.
• Volume patterns align with accumulation and shakeout phases.

Trade Strategy
• Add Zone: 1.15 – 1.18 NOK (on strength or dip support hold).
• Watch Zone: 1.22 – 1.26 NOK (for volume and continuation breakout).
• Profit Trim Zone: 1.55 – 1.65 NOK (historical upper range boundary).
• Stop Loss Consideration: Below 1.13 NOK (only if broken on volume).

Risk Management
• Watch for loss of support with accelerating volume.
• Avoid adding on breakdowns below 1.13 NOK.

Upcoming Catalysts
• Commercialization of solid-state batteries (volume shipments, integration deals).
• Revenue reports showing real customer traction.
• New strategic partnerships or OEM announcements.
• Market sentiment shift on green battery tech / reshoring themes.

Smart Money Summary
• Entry confirmation from Mirabella (~1.42 NOK), Alden (~mid-1.30s).
• 1.15 – 1.20 NOK has been a recurring buy zone across many sessions.
• Institutional rotation shows early traders out, long-term capital in.

Risks
• Early product and production phase.
• Funding might be needed in Q2 - 2025.
• General market sentiment due to high volatility at the moment.

Disclaimer: This post is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The content reflects personal analysis and opinion based on publicly available data. Please conduct your own due diligence or consult a licensed financial advisor before making any investment decisions. I hold a personal position as disclosed and may update or change it at any time without notice.

4月11日

註釋

So institutional investors steps in with a total of 52.250.000 new shares. 50 million from the private placement and additional 2.250.000 shares offered for their guarantee to enter. Provenue is 60 million NOK equaling a price of 1.148 NOK for each new share. Hence, the 1.148 NOK is the new support institutional investors are likely to defend by buying up in this area.

Looking at the graph it could be initial discussioins of the private placement were starting up in mid March where a new support around 1.15 NOK were forming.

4月11日

註釋

The annual 2024 report to be released today.

4月11日

註釋

Fundamental Catalyst – 2024 Annual Report
• Technology validated and partner samples delivered
• Equity ratio improved to -30% from -173% in 2023
• Roll-to-roll production active and stable
• No named customer yet, but 'Fortune 500' engagement reaffirmed
• Funding runway still limited to Q3–Q4 2025

4月12日

交易進行

The Fortune 500 company were not revealed in the annual report. But, is Samsung quietly working with Ensurge Micropower?

I’ve been following the solid-state microbattery space closely, and I believe there’s a realistic possibility that Ensurge Micropower is collaborating with Samsung Electro-Mechanics — based on public filings, patents, and technology disclosures.

Here’s the summary of what I’ve found:

1. Patent & Technology Parallels
• Both Ensurge and Samsung filed oxide-based, layered solid-state microbattery patents between 2020–2023.
• Similar stack architecture: multiple electrode layers with solid electrolytes (e.g., LiPON or oxide ceramics).
• Focus on ultrathin form factors, no liquid electrolyte, and compatibility with SMT (Surface Mount Tech).
• Both avoid lithium metal anodes: Ensurge uses “anodeless” deposition; Samsung uses symmetric electrode architecture.

Shared End-Use Target: Wearables
• Samsung is developing a solid-state battery for wearables (Galaxy Ring class), announced in Sept 2024.
• Ensurge also targets medical wearables, hearables, and IoT sensors with ultra-small battery footprints.

3. Timing Matches
• Ensurge began shipping test units to a Fortune 500 medical device company in mid-2024.
• Samsung announced its new prototype a few months later, citing 200 Wh/L energy density and MLCC-style layering.

4. Hypothetical Manufacturing Split
• Ensurge could deliver the battery core (stacked on 10 µm steel substrate).
• Samsung could add ceramic encapsulation and packaging (as their patents suggest).
• This allows Samsung to preserve IP on the packaging while fast-tracking innovation using Ensurge’s stack.

5. Strategic Fit

Samsung gains:
• Time-to-market
• Modular licensing control
• Battery format tailored for integration

Ensurge gains:
• A massive strategic partner
• Validation of its technology
• Potential scale-up for commercialization

————————————————
Not confirmed — but compelling

This is not financial advice, and nothing has been officially confirmed. But in my view, the technical and strategic fit is unusually strong — and worth watching, especially with Q2 updates May 15 and product launches on the horizon.

4月23日

註釋

Trade still active. Support keep being confirmed. However, strugling to break above what seems to be a descending triangle on the short term. Break above 1.28 - 1.30 with volume to confirm bullish momentum.

4月30日

註釋

Still awaiting more news updates on progress, JDA and partners.

Technically it looks bullish. From April 15 a symetrical triangle have been forming. A breakout to the upside have now occured. Exciting to see if this holds throughout the day and if we can get volume into the 1.30 - 1.40 range.

Trade still active.

5月10日

註釋

Trade still active.
Currently seeing a bullish momentum. Getting close to previous outlined trim zone. Technically the stock is close to overbought territory.

Q1 presentation next week. If there are no catalysts next week I’d consider to book some profit and probably trim my position by 30-40%.

Without news but continued bullish control it could be healthy to pull back from the ~1.60 level to the 1.35-1.45 area.

5月15日

註釋

The presentation and Q1 result gave more clarity. JDA or the reach of 28 layer batteries best case to be reached within the next 3 months. However, no negative information in my opinion compared to what was expected. Fundamentals are intact. The Fortune 500 company is more likely to be in the medical equipment domain. However, JDA talks with other potential clients have been initiated. However, the information did not match expectations since the price dropped significantly to end at 1.23. So it is likely the support around 1.10 to 1.20 is to be tested.

Trade still active.

5月17日

註釋

The noise from the AGM did push the price down to test the previous outlined support level. But the price action Friday 16. May showed significant buy interest in the 1,19-1,22 area. No dip below and support area still valid. The bullish channel on the bigger timeframe still in play. Technically and short term I would expect a bounce towards 1,40.

In the AGM several points from the agenda were removed. These mainly revolving around the management mandate to issue more shares in different scenarios, e.g. incentives. I see this as a signal from influental shareholders that the shift from a R&D phase to a commercial phase also involves a shift in strategy and mentality around management, funding, communication, investor trust and general governance of the company.

Fundamentally no bearish news did actually appear. The product is still unique in several areas. The market and demand exists and seems promising.

Of course the timeline can be questioned given the history of previous delays. This is where retail investors get impatient and institutional investors demand more transparency.

The good news is from my perspective, for the long term investor, there is more attention to how management lead the company. If they fail to deliver short term they will be sitting in hot chairs. Of course, huge acknowledgement for what they have achieved in the R&D phase. But the phase we enter now is a different game.

Could new faces be introduced to make this transition happen smootly? This is one of the questions I personally look forward to get an answer to.

Trade still active.